Special MRI to see how imatinib affects gist tumors
Part of Cancer, Digestive system clinical trials.
This study uses a special MRI technique to see how well imatinib is working on your GIST tumor. It may help doctors understand treatment response better and guide your care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with a gastrointestinal stromal tumor (GIST) through a biopsy.
- You are planning to take imatinib, a targeted therapy for GIST.
- You have at least one tumor that can be measured on imaging scans.
- You are 18 years of age or older.
- You are not pregnant or breastfeeding, and you can safely undergo an MRI.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at why some GIST tumors stop responding to standard treatments. It uses special imaging and genetic testing of tumor tissue to find resistance patterns, which may guide future treatment choices.
This trial tests a new drug, ziftomenib, combined with imatinib for people with advanced or spreading gastrointestinal stromal tumors (GIST) that have a KIT mutation. It may help if your GIST has gotten worse while on imatinib.
This study looks at how surgery for gastrointestinal stromal tumors (GIST) works, and collects tumor samples to study them under the microscope and by DNA testing. Your results may help researchers better predict tumor behavior and guide future treatment.
This trial tests whether giving imatinib (a drug that targets the C-KIT gene change) before surgery can help shrink the tumor and allow for a less invasive operation that saves your rectum.
This Phase 2 trial studies how to adjust and monitor imatinib (a targeted cancer medicine) based on drug levels in the blood. It may help people with GIST that has certain KIT or PDGFRA mutations but not the PDGFRA D842V type.
This trial studies whether taking imatinib before surgery can shrink or control high-risk gastrointestinal stromal tumors (GIST). If you qualify, you would receive imatinib as “neoadjuvant” (before the operation) and then move on to planned surgery.
Hear when a new Gastrointestinal Stromal Tumor (GIST) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.